Media coverage about Caladrius Biosciences (NASDAQ:CLBS) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Caladrius Biosciences earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.9983346238899 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Several brokerages have issued reports on CLBS. Zacks Investment Research downgraded shares of Caladrius Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, September 25th. HC Wainwright set a $7.00 target price on shares of Caladrius Biosciences and gave the company a “buy” rating in a research note on Friday, August 11th. Finally, ValuEngine raised shares of Caladrius Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.

Shares of Caladrius Biosciences (NASDAQ:CLBS) traded down 1.28% during mid-day trading on Thursday, reaching $3.08. 31,335 shares of the company’s stock traded hands. The company’s 50 day moving average is $3.67 and its 200-day moving average is $4.26. Caladrius Biosciences has a 52 week low of $2.65 and a 52 week high of $7.79.

Caladrius Biosciences (NASDAQ:CLBS) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $0.08. Caladrius Biosciences had a negative net margin of 84.10% and a negative return on equity of 180.68%. On average, equities research analysts anticipate that Caladrius Biosciences will post ($2.42) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Caladrius Biosciences (CLBS) Receives Media Sentiment Score of 0.09” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/10/26/caladrius-biosciences-clbs-receives-media-sentiment-score-of-0-09.html.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.

Insider Buying and Selling by Quarter for Caladrius Biosciences (NASDAQ:CLBS)

Receive News & Stock Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related stocks with our FREE daily email newsletter.